N-Acetylserotonin vs Melatonin: In-Vitro Controlled Release from Hydrophilic Matrix Tablets

Author(s): M. Vlachou*, G. Stavrou, A. Siamidi, S. Flitouri, V. Ioannidou, S. Mavrokordopoulos .

Journal Name: Letters in Drug Design & Discovery

Volume 16 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: N-Acetylserotonin (NAS, N-acetyl-5-hydroxytryptamine) is the immediate precursor of the neurohormone melatonin (MT, N-acetyl-5-methoxytryptamine), which regulates sleep and wake cycles. NAS is produced by the N-acetylation of serotonin and is converted to melatonin via the action of Acetylserotonin O-methyltransferase (ASMT). Like melatonin, NAS acts as an agonist on the melatonin receptors MT1, MT2, and MT3. However, as NAS is abundant in specific brain areas, separate from serotonin and melatonin, it may also have discrete central effects. Indicatively, it has been reported that NAS may play a role in the antidepressant effects of Selective Serotonin Reuptake Inhibitors (SSRIs) and Monoamine Oxidase Inhibitors (MAOIs).

Objective: To decipher the controlled release characteristics of the active substances (NAS and MT) in a quick initial pace, aiming at a satisfactory sleep-onset related anti-depressive profile and prolonged release, thereafter, targeting at coping with poor sleep quality problems.

Methods: A series of hydrophilic matrix tablets involving as excipients, hydroxypropylmethylcellulose (HPMC) K15M, low viscosity sodium alginate, lactose monohydrate, and polyvinylpyrrolidone (PVP) M.W.: 10.000 and 55.000) was developed and tested at two dissolution media (pH 1.2 and 7.4).

Results: The results showed that commonly used excipients with different physicochemical properties govern the controlled release of NAS and MT from solid matrix systems.

Conclusions: We have demonstrated how broadly used excipients affect the in vitro controlled release of NAS and MT from solid pharmaceutical formulations. Currently, we extend our studies on the controlled release of these drugs using various other biopolymers/formulants of different physicochemical characteristics, which will help to highlight the discrete release profiles of NAS and MT.

Keywords: N-Acetylserotonin, melatonin, matrix tablets, modified release, physicochemical, lactose monohydrate.

[1]
Tosini, G.; Ye, K.; Iuvone, P.M. N-acetylserotonin: neuroprotection, neurogenesis, and the sleepy brain. Neuroscience, 2012, 18, 645-653.
[2]
Nonno, R.; Pannacci, M.; Lucini, V.; Angeloni, D.; Fraschini, F.; Stankov, B.M. Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists. Br. J. Pharmacol., 1999, 127, 1288-1294.
[3]
Jang, S.W.; Liu, X.; Pradoldej, S.; Tosini, G.; Chang, Q.; Luvone, P.M.; Ye, K. () N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc. Natl. Acad. Sci. USA, 2010, 107, 3876-3881.
[4]
Vlachou, M.; Eikosipentaki, A.; Xenogiorgis, V. Pineal hormone melatonin: Solubilization studies in model aqueous gastrointestinal environments. Cur. Drug Del., 2006, 3, 255-265.
[5]
Vlachou, M.; Tsiakoulia, A.; Eikosipentaki, A. Controlled release of the pineal hormone melatonin from hydroxypropylmethylcellulose/sodium alginate matrices in aqueous media containing dioctyl sulfosuccinate. Curr. Drug Discov. Technol., 2007, 4, 31-38.
[6]
Vlachou, M.; Ioannidou, V.; Vertzoni, M.; Tsotinis, A.; Afroudakis, P.; Sugden, D. Controlled release from solid pharmaceutical formulations of two N-alkanoyl-4-methoxybicyclo[4.2.0]octa-1,3,5-trien-7-ethanamines with melatoninergic activity. Lett. Drug Des. Discov., 2015, 12, 259-262.
[7]
Zampakola, A.; Siamidi, A.; Pippa, N.; Demetzos, C.; Vlachou, M. Chronobiotic hormone melatonin: Comparative in vitro release studies from matrix tablets and liposomal formulations. Lett. Drug Des. Discov., 2017, 14, 476-480.
[8]
Khlibsuwan, R.; Pongjanyakul, T. Chitosan-clay matrix tablets for sustained-release drug delivery: Effect of chitosan molecular weight and lubricant. J. Drug Deliv. Sci. Technol., 2016, 35, 303-313.
[9]
Khan, K.A. The concept of dissolution efficiency. Communications. J. Pharm. Pharmacol., 1975, 27, 48-49.
[10]
Korsmeyer, R.W.; Doelker, G.F.P.; Peppas, N.A. Mechanism of potassium chloride from compressed, hydrophilic, polymeric matrices: Effect of entrapped air. J. Pharm. Sci., 1983, 72, 1189-1191.
[11]
Körner, A.; Piculell, L.; Iselau, F.; Wittgren, B.; Larsson, A. Influence of different polymer types on the overall release mechanism in hydrophilic matrix tablets. Molecules, 2009, 14, 2699-2716.
[12]
Rajabi-Siahboomi, A.R.; Bowtell, R.W.; Mansfield, P.; Henderson, A.; Davies, M.C.; Melia, C.D. Structure and behaviour in hydrophilic matrix sustained release dosage forms: 2, NMR-imaging studies of dimensional changes in the gel layer and core of HPMC tablets undergoing hydration. J. Cont. Rel, 1994, 31, 121-128.
[13]
Clasen, C.; Kulicke, W-M. Determination of viscoelastic and rheo-optical material functions of water-soluble cellulose derivatives. Prog. Polym. Sci., 2001, 26, 1839-1919.
[14]
Tukaram, B.N.; Rajagopalan, I.V.; Ikumar, S.P.S. The Effects of lactose, microcrystalline cellulose and dicalcium phosphate on swelling and erosion of compressed HPMC matrix tablets: Texture Analyzer. Iran. J. Pharm. Res., 2010, 9, 349-358.
[15]
Vlachou, M.; Siamidi, A.; Pareli, I.; Zampakola, A.; Konstantinidou, S. An account of modified release of melatonin from compression-coated, uncoated and bilayer tablets. J. Pharm. Pharm. Sci., 2016, 1, 10-14.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2019
Page: [347 - 352]
Pages: 6
DOI: 10.2174/1570180815666180404125519
Price: $58

Article Metrics

PDF: 17
HTML: 3